ZyVersa Therapeutics Inc Stock Price, News & Analysis

ZyVersa Therapeutics (OTCQB: ZVSA) reported Q2 2025 financial results and provided updates on its key drug development programs. The company activated its first clinical site for Phase 2a trial of VAR 200 in diabetic kidney disease (DKD) patients in June 2025, with interim results expected in Q4-2025. ZyVersa raised $2.05 million post-Q2 and $4.05 million year-to-date.

The company is advancing two main programs: VAR 200 for kidney diseases and IC 100 for inflammatory conditions. An IND-enabling obesity study for IC 100 is planned for Q4-2025. Financial results show Q2 2025 net losses of $2.2 million, improved from $2.8 million in Q2 2024, with cash on hand of $0.1 million as of June 30, 2025. The company requires additional financing to support ongoing operations and meet stated milestones.

[ "Secured $12 million in capital access through financing transactions", "Net loss improved by 20% year-over-year to $2.2 million in Q2 2025", "R&D expenses decreased by 42.2% year-over-year", "G&A expenses reduced by 20.1% compared to Q2 2024", "Advancing two promising drug candidates in large market opportunities ($30B kidney disease and $186B inflammatory disease markets by 2034)" ]

ZyVersa Therapeutics (NASDAQ:ZVSA) released a mid-year shareholder letter highlighting recent developments and R&D progress. The company secured $12 million in financing through two transactions: a $2M warrant inducement and a $10M Share Purchase Agreement. Their lead programs include VAR 200 for kidney diseases, currently in Phase 2a trials for diabetic kidney disease (DKD) with preliminary data expected in Q4-2025, and IC 100, an inflammasome inhibitor targeting obesity with cardiometabolic comorbidities.

The company recently transitioned to trading on the OTC Market while maintaining its ZVSA ticker. ZyVersa is advancing its clinical programs amid challenging biotech market conditions, with key milestones expected in H2 2025, including preliminary DKD trial data and initiation of IND-enabling preclinical studies for IC 100.

ZyVersa Therapeutics (Nasdaq: ZVSA), a clinical stage biopharmaceutical company, has entered into a warrant inducement agreement with a single institutional investor. The agreement includes the immediate exercise of existing Series A-2 and A-3 Warrants at a reduced exercise price of $0.67, generating gross proceeds of $2.0 million.

In exchange for exercising the existing warrants, the investor will receive new Series A-4 unregistered warrants to purchase up to 6,124,930 shares of common stock in a private placement. The new warrants will have an exercise price of $0.67 and will expire five years from stockholder approval. The transaction is expected to close around July 9, 2025.

ZyVersa Therapeutics (NASDAQ:ZVSA) has received FDA authorization for Emergency Compassionate Use of its Cholesterol Efflux Mediator™ VAR 200 in a patient with ApoCII amyloidosis, an ultra-rare kidney condition. The treatment will be administered at the University of Miami under the care of Dr. Alessia Fornoni, who is also the inventor of VAR 200.

The patient, who has shown continued kidney disease progression despite standard treatments, will receive VAR 200 following the protocol of the ongoing Phase 2a diabetic kidney disease (DKD) clinical trial. The drug was selected due to evidence of lipid deposition in the patient's kidney biopsy and VAR 200's demonstrated ability to reduce renal lipid accumulation in preclinical studies.

ZyVersa Therapeutics (NASDAQ: ZVSA) has activated its first clinical site for patient recruitment in a Phase 2a clinical trial of VAR 200, a potential first-in-class treatment for Diabetic Kidney Disease (DKD). The trial will be conducted at the Clinical Advancement Center in San Antonio, Texas, led by Dr. Pablo Pergola.

VAR 200 is designed to target renal lipotoxicity, a neglected pathogenic pathway in kidney disease that currently has no available treatments. The 16-week open-label study will evaluate VAR 200's efficacy and safety in patients with type 2 diabetes and DKD with proteinuria. Preliminary data is expected in H2-2025, with final results in H2-2026.

The drug has shown promising preclinical results in three types of kidney disease, demonstrating reduced cholesterol levels, protection against renal injury, and improved proteinuria.

ZyVersa Therapeutics (Nasdaq: ZVSA) has secured a share purchase agreement with Williamsburg Venture Holdings for up to $10 million to fund clinical development of its Cholesterol Efflux Mediator™ VAR 200 for chronic kidney diseases. The 24-month agreement allows ZyVersa to sell common stock to WVH at market-discounted prices, with ZyVersa maintaining full control over timing and amount of sales.

The agreement includes a 2.5% commitment share issuance to WVH based on purchased amounts. The funding aims to support VAR 200's development in the kidney disease market, which is projected to grow from $18 billion in 2024 to $30 billion by 2034.

ZyVersa Therapeutics (NASDAQ: ZVSA) highlights a new study published in Nature's Experimental and Molecular Medicine that reinforces the role of microglia-driven inflammation in Parkinson's and Alzheimer's diseases. The study validates ZyVersa's recent research showing how their Inflammasome ASC Inhibitor IC 100 could potentially modify disease progression by inhibiting NLRP1 inflammasome activation and reducing toxic phosphorylated alpha-synuclein levels. The global Parkinson's treatment market, currently valued at $6.6 billion (2024), is projected to reach $13.3 billion by 2034. The research, funded by the Michael J. Fox Foundation and conducted at the University of Miami School of Medicine, demonstrated that inflammatory microglia triggered pathological features of neurodegenerative diseases, including abnormal protein accumulation and neuroinflammation. ZyVersa plans to initiate proof-of-concept studies in Parkinson's disease animal models later this year.

ZyVersa Therapeutics (NASDAQ: ZVSA) reported Q1 2025 financial results and pipeline updates. The company posted a net loss of $2.3M, showing a 20.2% improvement from Q1 2024. Key developments include: 1) Phase 2a trial for VAR 200 in diabetic kidney disease to begin by Q2-end 2025; 2) Obesity-related preclinical study for IC 100 planned for Q2-end 2025; 3) IND application for IC 100 expected in H2 2025. The company raised $2.0M in Q1 but reports only $1.6M cash on hand, requiring additional financing for operations. R&D expenses decreased 49.5% to $259K, while G&A expenses dropped 18.5% to $1.9M. Recent data showed IC 100's potential in treating Parkinson's disease by blocking microglial inflammasome activation and reducing alpha-synuclein accumulation.

ZyVersa Therapeutics (NASDAQ: ZVSA) has announced strategic developments for its Inflammasome ASC Inhibitor IC 100, positioning it as a complementary therapy to GLP-1 agonists for treating obesity-related complications. The company highlights that while GLP-1 agonists are effective for weight loss, significant challenges remain, including muscle loss (20-40%) and high discontinuation rates (65% within one year). IC 100's preclinical data shows promise in reducing inflammation and improving metabolic parameters when combined with GLP-1 agonists. Key advantages include preserved lean mass, enhanced weight loss, and continued benefits after GLP-1 discontinuation. ZyVersa's development timeline includes initiating a preclinical study in H1-2025, submitting an IND application in H2-2025, and beginning Phase 1 trials in H1-2026. The global obesity crisis affects over 40% of Americans, with related costs projected to exceed $4.32 trillion annually by 2035.